Lincoln Pharmaceuticals (LPL) launches the much awaited Tinnex injection in India, as part of its agreement with Phafag AG, Switzerland to produce the Caroverine molecule for the treatment of Tinnitus commonly known as ringing in the ear. LPL is the sole manufacturer and distributor of Tinnex injection in India and the first company in the country to introduce a cure for Tinnitus. The launch of the Tinnex injection will provide relief to the millions of Indians suffering from this disease.
LPL has sold 500 ampoules of Tinnex injection all over India in the last one month. Already 70 per cent of the patients on the treatment have experienced relief from Tinnitus.
Speaking on the launch of the new drug Mahendra G Patel, MD, LPL said, “The launch of Tinnex injection makes Lincoln the first company to provide a treatment for Tinnitus in India. Tinnex injection will be a boon to patients who have been silently suffering from this disease and we at Lincoln are very happy to be a part of the solution.”
He further added, “With over 48 million people suffering from Tinnitus in India there is a huge potential for Tinnex injection. With our ongoing efforts to promote Tinnex all over India through well trained field people, we are aiming to create substantial demand in the first year itself. This product will further strengthen our position in Indian pharma industry and will go a long way in establishing the brand.”
The company has started marketing the product in ethical prescription markets in the otolaryngology segment approaching MS ENT (specialised in cochlear implants) surgeons. In addition to conducting continuing medical education (CME) to update physicians and other health professionals about the new drug and its availability. The CME involves a well structured detailed presentation made by trained Indian doctors.
In the second week of May 2011 Dr Ehrenberger, the main researcher of Caroverine molecule used in cochlear synaptic Tinnitus, will be coming down from Switzerland to conduct CME for the professionals to India.